Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-24 @ 2:25 PM
Ignite Modification Date:
2025-12-24 @ 2:25 PM
NCT ID:
NCT03875859
Brief Summary:
The primary purpose of this study is to determine if 8 weeks of topical remetinostat applied three times daily will suppress Squamous Cell Carcinoma.
Detailed Description:
The primary purpose of this study is:
* to determine if 8 weeks of topical remetinostat gel applied 3 times daily (TID) under occlusion will suppress SCC growth
* to determine the overall response rate (ORR) of SCCs after 8 weeks of treatment with topical remetinostat gel 1%, as measured by at least 30% decrease in greatest area (in mm2).
* Subjects with at least 1 biopsy-proven cutaneous SCC will be recruited for this study.
* Subjects will apply remetinostat gel 1% to at least 1 SCC.
* Non-invasive cutaneous SCC lesions, including Bowen's disease, are also eligible for this study
* There is 1 treatment option: Topical remetinostat gel 1% applied 3 times daily.
* The study is a single arm, open label design
* For purposes of ClinicalTrials.gov, there is no secondary outcome.
Study:
NCT03875859
Study Brief:
Protocol Section:
NCT03875859